nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC15A1—Lisinopril—dilated cardiomyopathy	0.291	0.344	CbGbCtD
Ceftriaxone—SLC22A11—Furosemide—dilated cardiomyopathy	0.238	0.281	CbGbCtD
Ceftriaxone—SLC22A8—Furosemide—dilated cardiomyopathy	0.138	0.164	CbGbCtD
Ceftriaxone—SLC22A6—Furosemide—dilated cardiomyopathy	0.0963	0.114	CbGbCtD
Ceftriaxone—ALB—Furosemide—dilated cardiomyopathy	0.082	0.0971	CbGbCtD
Ceftriaxone—Drug fever—Spironolactone—dilated cardiomyopathy	0.0103	0.0796	CcSEcCtD
Ceftriaxone—Local reaction—Furosemide—dilated cardiomyopathy	0.00338	0.0261	CcSEcCtD
Ceftriaxone—SLC22A11—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.003	0.161	CbGpPWpGaD
Ceftriaxone—Cholestasis—Furosemide—dilated cardiomyopathy	0.00247	0.019	CcSEcCtD
Ceftriaxone—Ataxia—Spironolactone—dilated cardiomyopathy	0.00235	0.0181	CcSEcCtD
Ceftriaxone—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00233	0.018	CcSEcCtD
Ceftriaxone—Glycosuria—Furosemide—dilated cardiomyopathy	0.00231	0.0178	CcSEcCtD
Ceftriaxone—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00229	0.123	CbGpPWpGaD
Ceftriaxone—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00229	0.0176	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00225	0.0174	CcSEcCtD
Ceftriaxone—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00219	0.0169	CcSEcCtD
Ceftriaxone—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00214	0.0165	CcSEcCtD
Ceftriaxone—Drug interaction—Furosemide—dilated cardiomyopathy	0.00202	0.0156	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00191	0.0147	CcSEcCtD
Ceftriaxone—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00191	0.103	CbGpPWpGaD
Ceftriaxone—Renal failure—Spironolactone—dilated cardiomyopathy	0.00189	0.0146	CcSEcCtD
Ceftriaxone—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.0018	0.0139	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00176	0.0136	CcSEcCtD
Ceftriaxone—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00164	0.0126	CcSEcCtD
Ceftriaxone—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0016	0.0123	CcSEcCtD
Ceftriaxone—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00158	0.0122	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00157	0.0121	CcSEcCtD
Ceftriaxone—Cephaloglycin—SLC22A5—dilated cardiomyopathy	0.00154	0.221	CrCbGaD
Ceftriaxone—Oliguria—Lisinopril—dilated cardiomyopathy	0.00153	0.0118	CcSEcCtD
Ceftriaxone—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00152	0.0117	CcSEcCtD
Ceftriaxone—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00151	0.0116	CcSEcCtD
Ceftriaxone—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.0015	0.0115	CcSEcCtD
Ceftriaxone—Cefepime—SLC22A5—dilated cardiomyopathy	0.00146	0.209	CrCbGaD
Ceftriaxone—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00144	0.0111	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00141	0.0108	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.0014	0.0108	CcSEcCtD
Ceftriaxone—Malaise—Spironolactone—dilated cardiomyopathy	0.00136	0.0105	CcSEcCtD
Ceftriaxone—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00135	0.0104	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00127	0.00982	CcSEcCtD
Ceftriaxone—Discomfort—Spironolactone—dilated cardiomyopathy	0.00127	0.00976	CcSEcCtD
Ceftriaxone—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00123	0.0095	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00123	0.00947	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00122	0.00944	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0012	0.00928	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00117	0.009	CcSEcCtD
Ceftriaxone—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00116	0.00897	CcSEcCtD
Ceftriaxone—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00115	0.00889	CcSEcCtD
Ceftriaxone—Cefixime—SLC22A5—dilated cardiomyopathy	0.00114	0.164	CrCbGaD
Ceftriaxone—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00113	0.00872	CcSEcCtD
Ceftriaxone—Ceftazidime—SLC22A5—dilated cardiomyopathy	0.00107	0.154	CrCbGaD
Ceftriaxone—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00107	0.00827	CcSEcCtD
Ceftriaxone—Cefdinir—SLC22A5—dilated cardiomyopathy	0.00106	0.151	CrCbGaD
Ceftriaxone—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00105	0.00813	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00104	0.00801	CcSEcCtD
Ceftriaxone—Renal failure—Furosemide—dilated cardiomyopathy	0.00103	0.00794	CcSEcCtD
Ceftriaxone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00101	0.00781	CcSEcCtD
Ceftriaxone—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000978	0.00754	CcSEcCtD
Ceftriaxone—Urticaria—Spironolactone—dilated cardiomyopathy	0.000976	0.00753	CcSEcCtD
Ceftriaxone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000971	0.00749	CcSEcCtD
Ceftriaxone—Ataxia—Lisinopril—dilated cardiomyopathy	0.00096	0.0074	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000956	0.00737	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000919	0.00709	CcSEcCtD
Ceftriaxone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000905	0.00698	CcSEcCtD
Ceftriaxone—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00089	0.00686	CcSEcCtD
Ceftriaxone—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000873	0.00673	CcSEcCtD
Ceftriaxone—Pruritus—Spironolactone—dilated cardiomyopathy	0.000869	0.0067	CcSEcCtD
Ceftriaxone—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000868	0.00669	CcSEcCtD
Ceftriaxone—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000865	0.00667	CcSEcCtD
Ceftriaxone—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000859	0.00662	CcSEcCtD
Ceftriaxone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000841	0.00648	CcSEcCtD
Ceftriaxone—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000825	0.00636	CcSEcCtD
Ceftriaxone—Dizziness—Spironolactone—dilated cardiomyopathy	0.000813	0.00627	CcSEcCtD
Ceftriaxone—Flatulence—Furosemide—dilated cardiomyopathy	0.000807	0.00622	CcSEcCtD
Ceftriaxone—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000802	0.00618	CcSEcCtD
Ceftriaxone—Vomiting—Spironolactone—dilated cardiomyopathy	0.000781	0.00602	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00078	0.00601	CcSEcCtD
Ceftriaxone—Rash—Spironolactone—dilated cardiomyopathy	0.000775	0.00597	CcSEcCtD
Ceftriaxone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000774	0.00597	CcSEcCtD
Ceftriaxone—Renal failure—Lisinopril—dilated cardiomyopathy	0.000773	0.00596	CcSEcCtD
Ceftriaxone—Headache—Spironolactone—dilated cardiomyopathy	0.00077	0.00594	CcSEcCtD
Ceftriaxone—Jaundice—Lisinopril—dilated cardiomyopathy	0.000767	0.00591	CcSEcCtD
Ceftriaxone—Anaemia—Furosemide—dilated cardiomyopathy	0.000757	0.00584	CcSEcCtD
Ceftriaxone—Agitation—Furosemide—dilated cardiomyopathy	0.000753	0.0058	CcSEcCtD
Ceftriaxone—Haematuria—Lisinopril—dilated cardiomyopathy	0.00075	0.00578	CcSEcCtD
Ceftriaxone—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000742	0.00572	CcSEcCtD
Ceftriaxone—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000734	0.00566	CcSEcCtD
Ceftriaxone—Leukopenia—Furosemide—dilated cardiomyopathy	0.000733	0.00565	CcSEcCtD
Ceftriaxone—Nausea—Spironolactone—dilated cardiomyopathy	0.00073	0.00563	CcSEcCtD
Ceftriaxone—Cefalotin—SLC22A5—dilated cardiomyopathy	0.000714	0.102	CrCbGaD
Ceftriaxone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000669	0.00515	CcSEcCtD
Ceftriaxone—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000668	0.00515	CcSEcCtD
Ceftriaxone—Flushing—Lisinopril—dilated cardiomyopathy	0.000655	0.00505	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000655	0.00505	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000646	0.00498	CcSEcCtD
Ceftriaxone—Chills—Lisinopril—dilated cardiomyopathy	0.000633	0.00488	CcSEcCtD
Ceftriaxone—Flatulence—Lisinopril—dilated cardiomyopathy	0.000606	0.00467	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000603	0.0324	CbGpPWpGaD
Ceftriaxone—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000602	0.00464	CcSEcCtD
Ceftriaxone—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000601	0.0323	CbGpPWpGaD
Ceftriaxone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.0006	0.00463	CcSEcCtD
Ceftriaxone—Pain—Furosemide—dilated cardiomyopathy	0.000572	0.00441	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00057	0.0044	CcSEcCtD
Ceftriaxone—Anaemia—Lisinopril—dilated cardiomyopathy	0.000568	0.00438	CcSEcCtD
Ceftriaxone—Malaise—Lisinopril—dilated cardiomyopathy	0.000554	0.00427	CcSEcCtD
Ceftriaxone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000551	0.00425	CcSEcCtD
Ceftriaxone—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00055	0.00424	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000547	0.00421	CcSEcCtD
Ceftriaxone—Palpitations—Lisinopril—dilated cardiomyopathy	0.000543	0.00419	CcSEcCtD
Ceftriaxone—Urticaria—Furosemide—dilated cardiomyopathy	0.000531	0.00409	CcSEcCtD
Ceftriaxone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000528	0.00407	CcSEcCtD
Ceftriaxone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000528	0.00407	CcSEcCtD
Ceftriaxone—Discomfort—Lisinopril—dilated cardiomyopathy	0.000517	0.00399	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000502	0.00387	CcSEcCtD
Ceftriaxone—Oedema—Lisinopril—dilated cardiomyopathy	0.000502	0.00387	CcSEcCtD
Ceftriaxone—Infection—Lisinopril—dilated cardiomyopathy	0.000498	0.00384	CcSEcCtD
Ceftriaxone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000493	0.0038	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000491	0.00379	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000485	0.00374	CcSEcCtD
Ceftriaxone—GLUL—Neuronal System—ABCC9—dilated cardiomyopathy	0.000482	0.0259	CbGpPWpGaD
Ceftriaxone—Pruritus—Furosemide—dilated cardiomyopathy	0.000473	0.00365	CcSEcCtD
Ceftriaxone—GLUL—Neuronal System—ACTN2—dilated cardiomyopathy	0.000462	0.0248	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000458	0.0246	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000457	0.00353	CcSEcCtD
Ceftriaxone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00045	0.00347	CcSEcCtD
Ceftriaxone—Dizziness—Furosemide—dilated cardiomyopathy	0.000442	0.00341	CcSEcCtD
Ceftriaxone—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000442	0.0034	CcSEcCtD
Ceftriaxone—Pain—Lisinopril—dilated cardiomyopathy	0.000429	0.00331	CcSEcCtD
Ceftriaxone—Vomiting—Furosemide—dilated cardiomyopathy	0.000425	0.00328	CcSEcCtD
Ceftriaxone—Rash—Furosemide—dilated cardiomyopathy	0.000422	0.00325	CcSEcCtD
Ceftriaxone—Dermatitis—Furosemide—dilated cardiomyopathy	0.000421	0.00325	CcSEcCtD
Ceftriaxone—Headache—Furosemide—dilated cardiomyopathy	0.000419	0.00323	CcSEcCtD
Ceftriaxone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000413	0.00319	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00041	0.00316	CcSEcCtD
Ceftriaxone—Urticaria—Lisinopril—dilated cardiomyopathy	0.000398	0.00307	CcSEcCtD
Ceftriaxone—Nausea—Furosemide—dilated cardiomyopathy	0.000397	0.00306	CcSEcCtD
Ceftriaxone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000397	0.00306	CcSEcCtD
Ceftriaxone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000397	0.00306	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—RAC1—dilated cardiomyopathy	0.000385	0.0207	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000382	0.0205	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00037	0.00285	CcSEcCtD
Ceftriaxone—Pruritus—Lisinopril—dilated cardiomyopathy	0.000355	0.00274	CcSEcCtD
Ceftriaxone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000343	0.00265	CcSEcCtD
Ceftriaxone—Dizziness—Lisinopril—dilated cardiomyopathy	0.000332	0.00256	CcSEcCtD
Ceftriaxone—Vomiting—Lisinopril—dilated cardiomyopathy	0.000319	0.00246	CcSEcCtD
Ceftriaxone—Rash—Lisinopril—dilated cardiomyopathy	0.000316	0.00244	CcSEcCtD
Ceftriaxone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000316	0.00244	CcSEcCtD
Ceftriaxone—Headache—Lisinopril—dilated cardiomyopathy	0.000314	0.00242	CcSEcCtD
Ceftriaxone—Nausea—Lisinopril—dilated cardiomyopathy	0.000298	0.0023	CcSEcCtD
Ceftriaxone—SLC22A11—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000273	0.0147	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—RAF1—dilated cardiomyopathy	0.000255	0.0137	CbGpPWpGaD
Ceftriaxone—SLC15A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000252	0.0136	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—TTN—dilated cardiomyopathy	0.000238	0.0128	CbGpPWpGaD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000234	0.0126	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—TTN—dilated cardiomyopathy	0.000227	0.0122	CbGpPWpGaD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000208	0.0112	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—ACTN2—dilated cardiomyopathy	0.000207	0.0111	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—ACTN2—dilated cardiomyopathy	0.000197	0.0106	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ANKRD1—dilated cardiomyopathy	0.000188	0.0101	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—TAZ—dilated cardiomyopathy	0.000177	0.00951	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—VCL—dilated cardiomyopathy	0.000176	0.00944	CbGpPWpGaD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000174	0.00934	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—VCL—dilated cardiomyopathy	0.000167	0.00899	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	0.000167	0.00895	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—SDHA—dilated cardiomyopathy	0.00016	0.0086	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000143	0.00766	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000139	0.00745	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000139	0.00745	CbGpPWpGaD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000137	0.00737	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000132	0.00708	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000129	0.00693	CbGpPWpGaD
Ceftriaxone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—CD36—dilated cardiomyopathy	0.000128	0.0069	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000128	0.00689	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000128	0.00689	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000122	0.00657	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000119	0.0064	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000119	0.00639	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000119	0.00639	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—SOD2—dilated cardiomyopathy	0.000116	0.00624	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000111	0.00594	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000109	0.00584	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000106	0.00568	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000106	0.00568	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.000106	0.00568	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—RAF1—dilated cardiomyopathy	0.000105	0.00564	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.83e-05	0.00528	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	9.45e-05	0.00508	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	9.17e-05	0.00493	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	9.07e-05	0.00488	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	9.03e-05	0.00485	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	9.01e-05	0.00484	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.83e-05	0.00474	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.83e-05	0.00474	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.21e-05	0.00441	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	7.79e-05	0.00419	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	7.52e-05	0.00404	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	7.5e-05	0.00403	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	7.17e-05	0.00385	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	7.16e-05	0.00385	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	6.96e-05	0.00374	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.55e-05	0.00352	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TTN—dilated cardiomyopathy	5.45e-05	0.00293	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	4.72e-05	0.00254	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	4.72e-05	0.00253	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	4.59e-05	0.00247	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	4.59e-05	0.00247	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	4.4e-05	0.00237	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GPX1—dilated cardiomyopathy	4.35e-05	0.00234	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.27e-05	0.00229	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CD36—dilated cardiomyopathy	4.23e-05	0.00227	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VCL—dilated cardiomyopathy	4.02e-05	0.00216	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—AGT—dilated cardiomyopathy	3.81e-05	0.00205	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	3.58e-05	0.00192	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	3.34e-05	0.00179	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	3.15e-05	0.00169	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	3.1e-05	0.00167	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TAZ—dilated cardiomyopathy	2.92e-05	0.00157	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	2.85e-05	0.00153	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.81e-05	0.00151	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SDHA—dilated cardiomyopathy	2.64e-05	0.00142	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.6e-05	0.0014	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.41e-05	0.0013	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.14e-05	0.00115	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.09e-05	0.00112	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	2.02e-05	0.00108	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.79e-05	0.000962	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CD36—dilated cardiomyopathy	1.72e-05	0.000924	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RAC1—dilated cardiomyopathy	1.62e-05	0.000871	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.61e-05	0.000864	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.57e-05	0.000842	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.41e-05	0.000758	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.07e-05	0.000578	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	9.31e-06	0.0005	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GPX1—dilated cardiomyopathy	7.16e-06	0.000385	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CD36—dilated cardiomyopathy	6.98e-06	0.000375	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AGT—dilated cardiomyopathy	6.28e-06	0.000337	CbGpPWpGaD
